Home › Companies › iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. proxy voting records

How asset managers voted at iTeos Therapeutics, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

• CUSIP issuer number46565G
• SEC CIK1808865

Recent shareholder votes

• June 17, 2025 annual meeting (2024-2025 proxy season): 4 items in iTeos Therapeutics, Inc.'s official results (Form 8-K, filed June 17, 2025); lowest support 73% of votes cast (Elect Director: Ann D. Rhoads). Full results and how funds voted.
• June 11, 2024 annual meeting (2023-2024 proxy season): 3 items in iTeos Therapeutics, Inc.'s official results (Form 8-K, filed June 13, 2024); lowest support 99.2% of votes cast (Elect Director: David K. Lee). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Earlier seasons list this company under the name ITEOS THERAPEUTICS INC., as its holders filed it.

Explore iTeos Therapeutics, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. This page is rebuilt weekly; built November 9, 2026.